---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-014099"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T19:37:56.493360+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Sagimet files updated investor presentation; no specific material changes disclosed

## Summary
- Filed an updated slide presentation dated February 14, 2025, for use in investor meetings.
- Presentation title: 'Targeting Metabolic Dysfunction with Novel Therapies to Treat MASH, Acne & Cancer'.
- No financial results, guidance changes, or material events are reported in the filing or exhibit excerpt.
- The 8-K is a routine update under Item 8.01 with no detailed new information provided.
- Confidence is low because the full presentation slides are not visible in the filing text.

## SEC filing metadata
- accession: 0001104659-25-014099
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465925014099/0001104659-25-014099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465925014099/tm256733d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-014099
- JSON: https://secwatch.observer/filing/0001104659-25-014099.json
- Plain text: https://secwatch.observer/filing/0001104659-25-014099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.